A mi­cro­cap biotech salves old wounds with pos­i­tive PhII re­port on sta­tus epilep­ti­cus, but plen­ty of ques­tions re­main

6 years ago
R&D

Take­da turns to emerg­ing mar­kets, West­ern Eu­rope in scram­ble to of­fload Shire debt — re­port

6 years ago
R&D

GSK in­fus­es $120M in­to next-gen man­u­fac­tur­ing fa­cil­i­ties at Up­per Meri­on, PA

6 years ago
Pharma

Re­pub­li­cans re­buke Pelosi drug pric­ing bill

6 years ago
Pharma
FDA+

Enan­ta's NASH drug bare­ly meets main goal in mid-stage study

6 years ago
R&D

Is the FTC about to force Roche to di­vest a key he­mo­phil­ia pro­gram be­fore green-light­ing Spark buy­out?

6 years ago
Deals

BioN­Tech lays out plans for $251M IPO; Trio teams up to form joint lab to re­search chron­ic lung dis­eases

6 years ago
News Briefing

Af­ter rocky hep C path, Achillion finds sur­er foot­ing with FDA break­through sta­tus

6 years ago
R&D

Med­Co builds its case for star cho­les­terol RNAi ther­a­py with two new pos­i­tive piv­otal stud­ies

6 years ago
R&D

Cana­di­an star re­searcher Bren­dan Frey bran­dish­es Deep Ge­nomic­s' first AI-dis­cov­ered drug

6 years ago
AI
Discovery

Top GSK/Vi­iV sci­en­tist who co-in­vent­ed an HIV block­buster books a trip to biotech

6 years ago
People
R&D

'Worse than ever,' Boston's biotechs stare down traf­fic cri­sis — prompt­ing call for more re­mote work­ing, flex hours

6 years ago
Pharma

Boehringer In­gel­heim backs Max Planck spin­out in tak­ing a shot at tough class of can­cer tar­gets

6 years ago
Financing
Startups

FDA en­dors­es Bavar­i­an Nordic's mon­key­pox vac­cine, mark­ing world's first ap­proval

6 years ago
R&D
FDA+

Reg­u­la­tors throw up an­oth­er hur­dle to Roche’s $4.3B Spark ac­qui­si­tion as ques­tions per­co­late over he­mo­phil­ia mar­ket ...

6 years ago
Deals
Cell/Gene Tx

Com­ing out of Chap­ter 11, Aege­ri­on jumps in­to wel­come arms of Irish phar­ma with big plans, fresh $60M for its drugs

6 years ago
Deals

No­var­tis ac­cus­es 2 AveX­is founders of al­ter­ing da­ta, stonewalling probe — but ex-CSO blasts back

6 years ago
Pharma
Cell/Gene Tx

Eli Lil­ly dish­es out first mile­stone pay­ment for Alzheimer's deal; ADC Ther­a­peu­tics, Viela Bio set terms for IPO

6 years ago
News Briefing

Hy­po­glycemia 'Epipen' clears Phase III, hur­tles to­ward FDA de­ci­sion

6 years ago
R&D

Cerev­el plots first late-stage move as Pfiz­er drug comes through in PhII Parkin­son's tri­al

6 years ago
R&D

Uro­Gen steers to­wards its first com­mer­cial drug launch, armed with strong da­ta on lead ther­a­py

6 years ago
R&D

Bay Area biotech hauls in $62M to pay the freight on ear­ly-stage CD33/CD3 T cell en­gager

6 years ago
R&D

Em­bat­tled AM­AG braces for Oc­to­ber FDA Mak­e­na ad­com, but it need not wor­ry — an­a­lyst

6 years ago
R&D
FDA+

Is Re­gen­eron los­ing its R&D mys­tique? An­a­lyst dis­counts big biotech’s run­ner-up de­vel­op­ment strat­e­gy in an ...

6 years ago
R&D
First page Previous page 913914915916917918919 Next page Last page
A service from the Financial Times